Questions?arveonix@protonmail.com•Telegram @arveonix

Last updated:

ARVEONIX CJC-1295 (without DAC) 5mg + Ipamorelin 5mg research product box and vial
Peptide blends · SKU CP10

CJC-1295 (without DAC) 5mg + Ipamorelin 5mg

$70.00 AUD
In stock
Free shipping Australia-wideOrders over $150

A research blend combining CJC-1295 without DAC and Ipamorelin to study complementary GHRH- and ghrelin-receptor signalling.

ProductCJC-1295 (without DAC) 5mg + Ipamorelin 5mg
SKUCP10
CategoryPeptide blends
Listed price$70.00 AUD
AvailabilityIn stock
Confirm current availability when making an enquiry.

What is CJC-1295 (without DAC) 5mg + Ipamorelin 5mg?

This blend combines CJC-1295 without DAC 5mg with Ipamorelin 5mg. The components engage different signalling pathways involved in pituitary growth-hormone regulation: CJC-1295 without DAC acts as a GHRH-pathway analogue, while Ipamorelin acts through the ghrelin receptor GHS-R1a.

The combination is therefore relevant to research into complementary endocrine signalling. Evidence for the blend itself should be distinguished from studies of either component used independently.

Research category

Peptide blends

ARVEONIX format

CJC-1295 (without DAC) 5mg + Ipamorelin 5mg · SKU CP10

Primary research context

GHRH and ghrelin-receptor pathways

Catalogue status

In stock · $70.00 AUD

GHRH and ghrelin-receptor pathways.

CJC-1295 without DAC is commonly described as a shorter-acting GHRH analogue, while Ipamorelin is a selective growth-hormone secretagogue receptor agonist. These pathways converge on pituitary regulation through different upstream receptors.

Combination research can examine temporal signalling, receptor interplay and downstream endocrine responses, but interpretation depends on formulation and experimental conditions.

Common research themes.

GHRH receptor

CJC-1295 without DAC is studied through the GHRH signalling pathway.

GHS-R1a

Ipamorelin is studied as a selective ghrelin-receptor agonist.

Complementary signalling

Research into how two upstream pathways influence pituitary signalling.

Combination design

Study of formulation, ratio and interaction effects.

Research considerations.

Research findings should always be interpreted within the experimental system in which they were produced. Cell, receptor, tissue, animal and human studies can answer different questions, and results from one model should not automatically be treated as established outcomes in another.

ARVEONIX product pages therefore focus on molecule identity, pathway biology and published research themes rather than presenting experimental observations as guaranteed effects. The information here is not a dosing, treatment or individual-use recommendation.

CJC-1295 FAQs.

What is in this blend?

It contains CJC-1295 without DAC 5mg and Ipamorelin 5mg.

What does without DAC mean?

It indicates a CJC-1295 research form without the Drug Affinity Complex modification associated with longer persistence.

Do the two components use the same receptor?

No. CJC-1295 without DAC acts through the GHRH pathway while Ipamorelin targets GHS-R1a.

Why are they studied together?

Researchers may study complementary regulation of pituitary growth-hormone signalling through two upstream pathways.

What is the SKU?

This blend is listed under SKU CP10.

Is this the same as the 10mg + 10mg blend?

The components are the same, but the listed total strengths differ.

Does this page provide a protocol?

No.